TY - JOUR
T1 - B lymphoma Moloney murine leukemia virus insertion region 1
T2 - An oncogenic mediator in prostate cancer
AU - Liu, Qipeng
AU - Li, Qiaqia
AU - Zhu, Sen
AU - Yi, Yang
AU - Cao, Qi
N1 - Publisher Copyright:
© The Author(s)(2018).
PY - 2019/5/1
Y1 - 2019/5/1
N2 - B lymphoma Moloney murine leukemia virus insertion region 1 (BMI1), a core member of polycomb repressive complex 1 (PRC1), has been intensely investigated in the field of cancer epigenetics for decades. Widely known as a critical regulator in cellular physiology, BMI1 is essential in self-renewal and differentiation in different lineages of stem cells. BMI1 also plays a significant role in cancer etiology for its involvement in pathological progress such as epithelial-mesenchymal transition (EMT) and cancer stem cell maintenance, propagation, and differentiation. Importantly, overexpression of BMI1 is predictive for drug resistance, tumor recurrence, and eventual therapy failure of various cancer subtypes, which renders the pharmacological targeting at BMI1 as a novel and promising therapeutic approach. The study on prostate cancer, a prevalent hormone-related cancer among men, has promoted enormous research advancements in cancer genetics and epigenetics. This review summarizes the role of BMI1 as an oncogenic and epigenetic regulator in tumor initiation, progression, and relapse of prostate cancer.
AB - B lymphoma Moloney murine leukemia virus insertion region 1 (BMI1), a core member of polycomb repressive complex 1 (PRC1), has been intensely investigated in the field of cancer epigenetics for decades. Widely known as a critical regulator in cellular physiology, BMI1 is essential in self-renewal and differentiation in different lineages of stem cells. BMI1 also plays a significant role in cancer etiology for its involvement in pathological progress such as epithelial-mesenchymal transition (EMT) and cancer stem cell maintenance, propagation, and differentiation. Importantly, overexpression of BMI1 is predictive for drug resistance, tumor recurrence, and eventual therapy failure of various cancer subtypes, which renders the pharmacological targeting at BMI1 as a novel and promising therapeutic approach. The study on prostate cancer, a prevalent hormone-related cancer among men, has promoted enormous research advancements in cancer genetics and epigenetics. This review summarizes the role of BMI1 as an oncogenic and epigenetic regulator in tumor initiation, progression, and relapse of prostate cancer.
KW - B lymphoma Moloney murine leukemia virus insertion region 1
KW - Oncogene
KW - Polycomb repressive complex 1
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85064837605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064837605&partnerID=8YFLogxK
U2 - 10.4103/aja.aja_38_18
DO - 10.4103/aja.aja_38_18
M3 - Review article
C2 - 29862993
AN - SCOPUS:85064837605
SN - 1008-682X
VL - 21
SP - 224
EP - 232
JO - Asian Journal of Andrology
JF - Asian Journal of Andrology
IS - 3
ER -
